May 23, 2023 11:29 AM EDT

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

Kyle LaHucik

Senior Reporter

Pfizer’s attempt to catch up in the weight loss market picked up steam on Monday with research showing the company’s GLP-1 agonist helped people with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Weight loss field ex­pands as Pfiz­er's oral GLP-1 gath­ers com­par­isons to Novo's We­govy in PhII da­ta

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence